Developing SENISCA's global network to meet future needs: grant applications, oligonucleotide synthesis, and pharmaceutical partners

SENISCA是埃克塞特大学的一家生物技术衍生公司，成立于2020年，致力于开发逆转细胞衰老(衰老疗法)的新方法。我们的创始人是分子和细胞生物学的世界领先者，并拥有专利保护，这是一项逆转细胞衰老的创新。这项创新的工作原理是恢复细胞‘微调’其基因表达的能力，使衰老的细胞恢复活力。在SENISCA上，我们正在利用关于细胞如何以及为什么衰老的知识，开发基于寡核苷酸的新一代干预措施，逆转衰老细胞的衰老时钟，并针对衰老的疾病和美学迹象。由于寡核苷酸疗法是全球增长最快的治疗部门之一，尖端细胞递送技术正在不断和快速的发展中。为了跟上这些发展，SENISCA需要一个强大的内部团队来确保世界领先的寡核苷酸合成和细胞交付许可合作伙伴关系的任务。这将是我们能够为我们的药物流水线进入第一阶段到第三阶段临床测试阶段的关键成功因素，并确保SENISCA成为全球领先的寡核苷酸治疗公司。这些合作关系的成功还将为竞标欧盟合作的赠款机会提供坚实的基础，并为未来的共同开发药物合作伙伴打开大门。我们将向SENISCA团队的成员分配研究任务，将研究分包给药物开发市场专家，并寻找药物合作伙伴机构来帮助我们寻找合作伙伴。我们还计划在2022年初至少参加一次网络活动/会议(在线或亲自参加)，以扩大我们的国际网络和知名度。该项目将引领老龄领域的创新。SENISCA正在为特发性肺纤维化(IPF)、骨关节炎(OA)和老年性黄斑变性(AMD)等与年龄相关的疾病提出有效的治疗方法(并有可能治愈)。目前，这些疾病的治疗有限，无法治愈。通过开始寻找全球合作伙伴，我们将允许科学知识和专业知识的交流，我们将加快SENISCA的研发和商业化道路。

SENISCA is a biotech spinout company from the University of Exeter, founded in 2020 and dedicated to the development of new approaches to reverse cellular senescence (senotherapeutics). Our founders are world leaders in molecular and cellular biology and have patent-protected an innovation for the reversal of cell aging. This innovation works by restoring the ability of cells to 'fine tune' the expression of their genes to rejuvenate aged cells.At SENISCA, we are using this knowledge, concerning how and why cells become senescent, to develop a new generation of oligonucleotide-based interventions, to turn back the ageing clock in old cells and to target the diseases and aesthetic signs of ageing.Because oligonucleotide therapeutics is one of the fastest-growing therapeutic sectors globally, cutting edge cell delivery technologies are in constant and fast-moving development. To stay abreast of these developments, SENISCA needs to dedicate a strong internal team to the task of securing world leading partnerships for oligonucleotide synthesis and cell delivery in-licensing. This will be a key success factor in our ability to reach Phase 1 to Phase 3 clinical-testing stage for our drug pipeline, and ensure that SENISCA becomes a leading Oligonucleotide therapeutics company globally. The success of these partnerships will also provide a solid foundation to bid for collaborative EU-based grant opportunities and open the door to future co-development pharmaceutical partnerships.We will be assigning research tasks to members of the SENISCA team, sub-contracting research to a drug development market specialist, and sourcing a pharmaceutical partnering agency to assist us with our partner search. We also aim to attend at least one networking event/conference in early 2022 (either online or in person) to increase our international network and visibility.This project will lead to innovation within the senescence field. SENISCA is proposing effective treatments (and potentially cures) for age-related diseases such as Idiopathic Pulmonary Fibrosis (IPF), Osteoarthritis (OA) and Age-related Macular Degeneration (AMD). These diseases currently have limited treatment and no cure. By starting the search for global partners, we will allow for the exchange of scientific knowledge and expertise, and we will accelerate SENISCA's R&D and route towards commercialisation.